A trial evaluating the effect of Boehringer-Ingelheim’s Jardiance® (empagliflozin) in adults with chronic kidney disease will stop early following an assessment of positive efficacy.
“We are thrilled that the trial has shown that empagliflozin is beneficial among the patients studied,” said professor Richard Haynes, co-principal investigator. “We are very grateful to all of the participants who have made this trial possible and look forward to sharing detailed trial results later this year.”